Molecular docking study of the acetylcholinesterase inhibition

1. Atlee JL. Complications in Aanesthesia. Philadelphia: Saunders Elsevier; 2007.Search in Google Scholar

2. Burns A, Iliffe S. Alzheimer’s disease. BMJ. 2009;338:b158.10.1136/bmj.b158Search in Google Scholar

3. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J. 1978;2(6150):1457-9.10.1136/bmj.2.6150.1457Search in Google Scholar

4. Perry EK, Walker M, Grace J, Perry RH. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 1999; 22(6):273-80.10.1016/S0166-2236(98)01361-7Search in Google Scholar

5. Draczkowski P, Tomaszuk A, Halczuk P, Strzemski M, Matosiuk D, Jozwiak K. Determination of affinity and efficacy of acetylcholinesterase inhibitors using isothermal titration calorimetry. Biochim Biophys Acta Gen Subj. 2016;1860(5):967-74.10.1016/j.bbagen.2015.11.00626586471Search in Google Scholar

6. Dhanjal JK, Sharma S, Grover A, Das A. Use of ligand-based pharmacophore modeling and docking approach to find novel acetylcholinesterase inhibitors for treating Alzheimer’s. Biomed Pharmacother. 2015;71:146-52.10.1016/j.biopha.2015.02.01025960230Search in Google Scholar

7. Chigurupati S, Selvaraj M, Mani V, Selvarajan KK, Mohammad JI, Kaveti B, et al. Identification of novel acetylcholinesterase inhibitors: indolopyrazoline derivatives and molecular docking studies. Bioorg Chem. 2016;67:9-17.10.1016/j.bioorg.2016.05.00227231830Search in Google Scholar

8. Lane RM, Kivipelto M, Greig NH. Acetylcholinesterase and its inhibition in Alzheimer disease. Clin Neuropharmacol. 2004;27:141-9.10.1097/00002826-200405000-0001115190239Search in Google Scholar

9. Galisteo M, Rissel M, Sergent O, Chevanne M, Cillard J, Guillouzo A, et al. Hepatotoxicity of tacrine: occurrence of membrane fluidity alterations without involvement of lipid peroxidation. J Pharmacol Exp Ther. 2000;294:160-7.Search in Google Scholar

10. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Db Syst Rev. 2006;1:CD005593.10.1002/14651858.CD005593900634316437532Search in Google Scholar

11. Alldredge KB. Applied therapeutics: The clinical use of drugs. 10^th ed. Baltimore: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013.Search in Google Scholar

12. Chitranshi N, Gupta S, Tripathi PK, Seth PK. New molecular scaffolds for the design of Alzheimer’s acetylcholinesterase inhibitors identified using ligand- and receptor-based virtual screening. Med Chem Res. 2013;2:2328-45.10.1007/s00044-012-0227-3Search in Google Scholar

13. Quinn DM. Acetylcholinesterase: Enzyme structure, reaction dynamics, and virtual transition states. Chem Rev. 1987;87:955-75.10.1021/cr00081a005Search in Google Scholar

14. Szegletes T, Mallender WD, Thomas PJ, Rosenberry TL. Substrate binding to the peripheral site of acetylcholinesterase initiates enzymatic catalysis. Substrate inhibition arises as a secondary effect. Biochemistry. 1999;38:122-33.10.1021/bi98135779890890Search in Google Scholar

15. Bourne Y, Taylor P, Radic Z, Marchot P. Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site, EMBO J. 2003;22:1-12.10.1093/emboj/cdg005Search in Google Scholar

16. Dvir H, Silman I, Harel M, Rosenberry TL, Sussman JL. Acetylcholinesterase: From 3D structure to function. Chem Biol Interact. 2010;187:10-22.10.1016/j.cbi.2010.01.042289430120138030Search in Google Scholar

17. Stahura FL, Bajorath J. Virtual screening methods that complement HTS. Comb Chem High Throughput Screen. 2004; 7:259-69.10.2174/138620704332870615200375Search in Google Scholar

18. Cheung J, Gary EN, Shiomi K, Rosenberry TL. Structures of human acetylcholinesterase bound to dihydrotanshinone I and territrem B show peripheral site flexibility. ACS Med Chem Lett. 2013;11:1091-6.10.1021/ml400304w402715224900610Search in Google Scholar

19. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001:46:3-26.Search in Google Scholar

20. Grosdidier A. Conception d’un logiciel de docking et applications dans la recherche de nouvelles molécules actives. PhD Thesis : Joseph Fourier University, France; 2007.Search in Google Scholar

21. Beri V, Wildman SA, Shiomi K, Al-Rashid Z, Cheung J, Rosenberry TL. The natural product dihydrotanshinone I provides a prototype for uncharged inhibitors that bind specifically to the acetylcholinesterase peripheral site with nanomolar affinity. Biochem. 2013; 52: 7486-99.10.1021/bi401043w24040835Search in Google Scholar